EUVIMEDEUVIMED entdecken
Crossref

Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR‐2 and EGFR T790M : Molecular docking, ADMET, design, and syntheses

Marwa Alsulaimany, Sanadelaslam S A El-Hddad, Zuhir S M Akrim, Ahmed K B Aljohani, Basmah Almohaywi, Omar M Alatawi, Sara A Almadani, Hussam Y Alharbi, Majed S Aljohani, Samar F Miski, Read Alghamdi, Khaled El-Adl

Archiv der Pharmazie · 2024

DOI: 10.1002/ardp.202400389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Marwa Alsulaimany und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy & Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina, Saudi Arabia. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, ErbB Receptors, Molecular Docking Simulation, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel inhibitors of epidermal growth factor receptor (EGFR) T790M /vascular endothelial growth factor receptor‐2 (VEGFR‐2) were synthesized based on the iodoquinazoline scaffold linked to different heteroaromatic, aromatic, and/or aliphatic moieties. The novel derivatives were in vitro examined for anticancer activities against A549, HCT116, michigan cancer foundation‐7 (MCF‐7), and HepG2 cells. Molecular modeling was applied to discover their orientation of binding with both VEGFR‐2 and EGFR active sites. Compounds 8d , 8c , 6d , and 6c indicated the highest cytotoxicity with IC 50 = 6.00, 6.90, 6.12 and 6.24 µM, 7.05, 7.35, 6.80, and 6.80 µM, 5.75, 7.50, 6.90, and 6.95 µM, and 6.55, 7.88, 7.44, and 7.10 µM against the A549, HepG2, HCT116, and MCF‐7 cell lines, correspondingly. The cytotoxicity against normal VERO (normal african green monkey kidney cells) of the extremely active eight compounds 6a–d and 8a–d was evaluated. Our compounds exhibited low toxicity concerning normal VERO cells with IC 50 = 45.66–51.83 μM. Furthermore, inhibition assays for both the EGFR T790M and VEGFR‐2 enzymes were done for all compounds. Remarkable inhibition of EGFR T790M activity was achieved with compounds 6d , 8d , 6c , and 8c at IC 50 = 0.35, 0.42, 0.48, and 0.50 µM correspondingly. Moreover, remarkable inhibition of VEGFR‐2 activity was achieved with compounds 8d , 8c , 6d , and 6c at IC 50 = 0.92, 0.95, 1.00, and 1.20 µM correspondingly. As planned, derivatives 6d , 8d , 6c , and 8c presented exceptional inhibition of both EGFR T790M /VEGFR‐2 activities. Finally, in silico absorption, distribution, metabolism, excretion and toxicity (ADMET) studies were made for the highly active four compounds 6c , 6d , 8c , and 8d in comparison with erlotinib and sorafenib as reference standards.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2ErbB ReceptorsMolecular Docking SimulationAntineoplastic AgentsDrug DesignQuinazolinesHumansStructure-Activity RelationshipAnimalsMolecular StructureChlorocebus aethiopsDrug Screening Assays, AntitumorProtein Kinase InhibitorsDose-Response Relationship, DrugVero CellsCell ProliferationCell Line, Tumor

Stichwörter der Autor:innen

ADMETanticanceriodoquinazolinestyrosine kinase

Substanzen

Vascular Endothelial Growth Factor Receptor-2ErbB ReceptorsAntineoplastic AgentsKDR protein, humanQuinazolinesProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Pharmacognosy & Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina, Saudi Arabia.
  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Omar Almukhtar University, Libya.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Omar Almukhtar University Al-Bayda, Libya.
  • Pharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Department of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.

Förderung

  • None

Zitieren

APA

Alsulaimany, M., El-Hddad, S. S. A., Akrim, Z. S. M., Aljohani, A. K. B., Almohaywi, B., Alatawi, O. M., Almadani, S. A., Alharbi, H. Y., Aljohani, M. S., Miski, S. F., Alghamdi, R., & El-Adl, K. (2024). Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR‐2 and EGFR T790M : Molecular docking, ADMET, design, and syntheses. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400389

Vancouver

Alsulaimany M, El-Hddad SSA, Akrim ZSM, Aljohani AKB, Almohaywi B, Alatawi OM, et al. Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR‐2 and EGFR T790M : Molecular docking, ADMET, design, and syntheses. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400389

BibTeX
@article{Alsulaimany2024,
  author = {Alsulaimany, Marwa and El-Hddad, Sanadelaslam S A and Akrim, Zuhir S M and Aljohani, Ahmed K B and Almohaywi, Basmah and Alatawi, Omar M and Almadani, Sara A and Alharbi, Hussam Y and Aljohani, Majed S and Miski, Samar F and Alghamdi, Read and El-Adl, Khaled},
  title = {Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR‐2 and EGFR T790M : Molecular docking, ADMET, design, and syntheses},
  journal = {Archiv der Pharmazie},
  year = {2024},
  doi = {10.1002/ardp.202400389}
}
Kostenlos starten →